Memantine Sandoz

Memantine Hydrochloride, the active ingredient in Memantine Sandoz, is a non‑competitive NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition, daily functioning and behavioral symptoms.

GNH USA supplies Memantine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows strict quality and regulatory standards, continually ensuring product integrity across global markets.

Memantine Sandoz is used in the management of neurodegenerative disorders, specifically Alzheimer’s disease, by modulating glutamatergic neurotransmission.

Moderate to severe Alzheimer’s disease: improves cognitive function, daily living activities and behavioral symptoms. Mild to moderate Alzheimer’s disease (off‑label): may provide modest cognitive benefit in early stages. Behavioral disturbances in Alzheimer’s disease: can help reduce agitation and aggression.

Memantine Sandoz may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion

Serious or Rare Side Effects: - Seizures - Hallucinations or psychosis - Severe allergic reactions (rash, swelling, anaphylaxis)

When prescribing Memantine Sandoz, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes before and during therapy. - History of seizures: use with caution and monitor for seizure activity. - Concurrent use with other NMDA antagonists: avoid combined use to reduce risk of excessive CNS depression. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Memantine Sandoz can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: additive central nervous system effects may increase confusion. - Ketamine: combined NMDA antagonism can lead to severe neurotoxicity. - Other NMDA receptor antagonists: risk of profound CNS depression.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: memantine may enhance blood pressure‑lowering effects. - Diuretics: increased risk of dehydration and electrolyte imbalance. - Anticholinergic drugs: may worsen cognitive side effects.